This Article Full Text Full Text (PDF) All Versions of this Article: 39/4/1307    most recent STROKEAHA.107.499822v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hobbs, C. Articles by Dingley, J. Search for Related Content PubMed PubMed Citation Articles by Hobbs, C. Articles by Dingley, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Related Collections Secondary prevention Animal models of human disease Other Treatment Neuroprotectors

(Stroke. 2008;39:1307.)
© 2008 American Heart Association, Inc.

Original Contributions

Xenon and Hypothermia Combine Additively, Offering Long-Term Functional and Histopathologic Neuroprotection After Neonatal Hypoxia/Ischemia

Catherine Hobbs, PhD; Marianne Thoresen, MD, PhD; Alexander Tucker, BA; Kristian Aquilina, FRCS; Ela Chakkarapani, MRCPCH John Dingley, MD

From the Department of Clinical Sciences at South Bristol (C.H., M.T., A.T., K.A., E.C., J.D.), University of Bristol, Bristol, and the School of Medicine (J.D.), University of Wales, Swansea, UK.

Correspondence to Prof Marianne Thoresen, St. Michael’s Hospital, Level D, Department of Child Health, CSSB, University of Bristol, Bristol, BS2 8EG, UK. E-mail marianne.thoresen{at}bristol.ac.uk

Background and Purpose— Hypoxic/ischemic (HI) brain injury affects 1 to 6 per 1000 live human births, with a mortality of 15% to 20%. A quarter of survivors have permanent disabilities. Hypothermia is the only intervention that improves outcome; however, further improvements might be obtained by combining hypothermia with additional treatments. Xenon is a noble anesthetic gas with an excellent safety profile, showing great promise in vitro and in vivo as a neuroprotectant. We investigated combinations of 50% xenon (Xe_50%) and hypothermia of 32°C (HT_32°C) as a post-HI therapy.

Methods— An established neonatal rat HI model was used. Serial functional neurologic testing into adulthood 10 weeks after injury was performed, followed by global and regional brain histopathology evaluation.

Results— In the combination Xe_50%HT_32°C group, complete restoration of long-term functional outcomes was seen. Hypothermia produced improvement on short- (P<0.001) and long- (P<0.001) term functional testing, whereas Xe_50% alone predominantly improved long-term function (P<0.05), suggesting that short-term testing does not always predict eventual outcome. Similarly, the Xe_50%HT_32°C combination produced the greatest (71%) improvement in global histopathology scores, a pattern mirrored in the regional scores, whereas Xe_50% and HT_32°C individually produced smaller improvements (P<0.05 and P<0.001, respectively). The interaction between the 2 treatments was additive.

Conclusions— The xenon/hypothermia combination additively confers greater protection after HI than either treatment alone. The functional improvement is almost complete, is sustained long term, and is accompanied by greatly improved histopathology. The unique safety profile differentiates xenon as an attractive combination therapy with hypothermia to improve the otherwise bleak outcome from neonatal HI.

Key Words: xenon • neuroprotection • neonatal ischemia • hypoxia/ischemia